Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

Lonza Chr Hansen Microbiome Manufacturing

News and Trends 3 Apr 2019

Joint Venture First to Offer Seamless Manufacturing of Microbiome Therapies

Lonza, a Swiss pharma supplier, and Chr. Hansen, a Danish supplier of bacterial products, are teaming up to enter the promising microbiome space. Together, the two companies will invest €90M in the creation of the first company that will offer a full supply chain to produce treatments made of live bacteria. Their 50/50 joint venture […]

April 3, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

chemical burns manchester cornea stem cells

News and Trends 3 Apr 2019

UK Scientists Activate Stem Cells to Heal Corneal Injuries

A group of researchers in the UK has developed a potential treatment for corneal injuries, such as those caused by chemical burns, by making surrounding tissue softer and letting stem cells regenerate damaged tissue. The cornea is a transparent tissue that is important for focusing light onto the retina and guarding entry into the eye. […]

April 3, 2019 - 2 minutesmins - By Jonathan Smith

More News! 3 Apr 2019

€21M Series A to Finance Belgian Biotech’s Regenerative Antibodies

The Belgian biotech AgomAb has raised €21M and partnered with the Dutch biotech argenx to develop antibody treatments that could regenerate damaged tissue. The round was led by the Belgian investor V-Bio Ventures and Advent France Biotechnology. AgomAb will use the big Series A funding to test antibody treatments for fibrosis in clinical trials, as […]

April 3, 2019 - 2 minutesmins - By Jonathan Smith

sartorius wordpress cover

Infographics 3 Apr 2019

Infographic: The Importance of New Biological Drug Characterization

By 2023, the monoclonal antibodies market is expected to reach a staggering $130B. The potential of monoclonal antibodies and other biologic drugs is huge. They are promising treatments for severe diseases and can improve or save patients’ lives. Check out our shiny new infographic on why these biologics need to be characterized properly! Download the […]

April 3, 2019 - 1 minutemin - By External Contributor

synbio genome artificial C eth2.0 bacteria 1

More News! 2 Apr 2019

Swiss Scientists Make Synthetic Bacterial Genome Using Computers

Synthetic biology researchers at ETH Zurich are the first to construct a simplified artificial bacterial genome with the help of computer algorithms, which could lead to better-engineered microorganisms for the production of therapeutics and other chemicals. Back in 2008, US researchers led by the famous biologist John Craig Venter made headlines for synthesizing the genome […]

April 2, 2019 - 3 minutesmins - By Jonathan Smith

Best Biotech Companies Europe

Best in Biotech 2 Apr 2019

The 8 Best Biotech Companies in Europe’s History

We’ve put together a list of the best biotech companies in Europe to celebrate their invaluable contributions to science and the development of the booming industry that biotech is today. Though the beginnings of the biotech industry are commonly traced back to the US, Europe has stepped up as a major contender and ally in […]

April 2, 2019 - 8 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT

Spare Parts Science Gallery London

News and Trends 2 Apr 2019

Spare Parts: Exploring the Science of Repairing the Human Body

London’s Science Gallery has gathered scientists and artists to create an exhibition that lets visitors peek at a not-so-distant future where custom implants and organ regeneration become the norm. The field of regenerative medicine has taken huge strides forward in recent years. Today, there’s talk of stem cells, smart implants, and 3D-printed organs all over […]

April 2, 2019 - 8 minutesmins - By Clara Rodríguez Fernández

cambridge innovation capital fund university

News and Trends 1 Apr 2019

Cambridge Fund Raises €175M to Supercharge Local Life Sciences Ecosystem

The UK venture capital fund Cambridge Innovation Capital, backed by the University of Cambridge, has raised €175M (£150M) to spend on life science and technology companies in the Cambridge area. The money will support the 25 companies in the fund’s portfolio, including the biotech Bicycle Therapeutics, whose peptide-toxin molecules are in clinical trials for the […]

April 1, 2019 - 2 minutesmins - By Jonathan Smith

Darrin Disley cover 2

Interview 1 Apr 2019

Chasing the Holy Grail of Cell Therapy

Biotech entrepreneur Darrin Disley, ex-CEO and co-founder of the successful Cambridge gene editing biotech Horizon Discovery, has a new quest — creating the perfect cell therapy. He spoke to me about his position as CEO of new biotech Mogrify and why he thinks now is a good time to get into cell therapy. Following the […]

April 1, 2019 - 7 minutesmins - By Helen Albert

Inivata cancer liquid biopsy

News and Trends 29 Mar 2019

Liquid Biopsy for Lung Cancer Gets €46M Boost

Inivata has raised a €46M (£40M) Series B round that will further advance the commercialization of the company’s blood test for lung cancer as well as the development of new tests. Investors include Woodford patient Capital Trust, IP Group, Cambridge Innovation Capital, Johnson & Johnson Innovation and RT Ventures. Based in both the US and […]

March 29, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

Cellnovo diabetes artificial pancreas

News and Trends 29 Mar 2019

French Diabetes Company Cellnovo Goes into Administration

Paris-based Cellnovo has cut down on staff as well as stopped manufacturing and selling its diabetes management system as the company found itself unable to scale up. Until this week, Cellnovo was selling a diabetes management system consisting of a small insulin pump that was controlled via smartphone. Hundreds of diabetics using this technology have […]

March 29, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

Galapagos Gilead filgotinib rheumatoid arthritis

News and Trends 29 Mar 2019

Galapagos Nears First Drug Approval with Phase III Success in Rheumatoid Arthritis

Galapagos has released positive data from two phase III trials testing its flagship drug candidate, filgotinib, that will let the company and its partner Gilead apply for marketing approval. 20 years after its foundation, Galapagos is finally approaching the finish line. Yesterday, the company has shared positive data from two clinical trials that together enrolled […]

March 29, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT